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ReviewWHAT THIS PAPER ADDS
Previous meta-analyses have identified a higher risk of all cause death using paclitaxel coated devices in the
femoropopliteal arteries, and of the composite of all cause death and major amputation in the infrapopliteal
arteries. A systematic review and meta-analysis was performed of randomised controlled trials to investigate the
long term risk of major amputation alone associated using paclitaxel drug coated balloons (DCB) in the lower limbs.
A significantly higher long term risk of major limb loss using DCB in the femoropopliteal and/or infrapopliteal
arteries was documented. There was also evidence of a significant non-linear dose response relationship.Objective: There have been concerns about the long term safety of paclitaxel coated devices in the lower limbs. A
formal systematic review and meta-analysis of randomised controlled trials (RCTs) was performed to examine the
long term risk of major amputation using paclitaxel coated balloons in peripheral arterial disease (PAD).
Method: This systematic review was registered with PROSPERO (ID 227761). A broad bibliographic search was
performed for RCTs investigating paclitaxel coated balloons in the peripheral arteries (femoropopliteal and
infrapopliteal) for treatment of intermittent claudication or critical limb ischaemia (CLI). The literature search
was last updated on 20 February 2021 without any restrictions on publication language, date, or status.
Major amputations were analysed with time to event methods employing one and two stage models.
Sensitivity and subgroup analyses, combinatorial meta-analysis, and a multivariable dose response meta-
analysis to examine presence of a biological gradient were also performed.
Results: In all, 21 RCTs with 3 760 lower limbs were analysed (52% intermittent claudication and 48% CLI; median
follow up two years). There were 87 major amputations of 2 216 limbs in the paclitaxel arms (4.0% crude risk)
compared with 41 major amputations in 1 544 limbs in the control arms (2.7% crude risk). The risk of major
amputation was significantly higher for paclitaxel coated balloons with a hazard ratio (HR) of 1.66 (95% CI 1.14
e 2.42; p ¼ .008, one stage stratified Cox model). The prediction interval was 95% CI 1.10 e 2.46 (two stage
model). The observed amputation risk was consistent for both femoropopliteal (p ¼ .055) and infrapopliteal
(p ¼ .055) vessels. Number needed to harm was 35 for CLI. There was good evidence of a significant non-linear
dose response relationship with accelerated risk per cumulative paclitaxel dose (chi square model p ¼ .007).
There was no evidence of publication bias (p ¼ .80) and no significant statistical heterogeneity between studies
(I2 ¼ 0%, p ¼ .77). Results were stable across sensitivity analyses (different models and subgroups based on
anatomy and clinical indication and excluding unpublished trials). There were no influential single trials. Level of
certainty in evidence was downrated from high to moderate because of sparse events in some studies.
Conclusion: There appears to be heightened risk of major amputation after use of paclitaxel coated balloons in
the peripheral arteries. Further investigations are warranted urgently.responding author. Department of Interventional Radiology, Patras University Hospital, Rion, 26504, Greece.
il address: katsanos@med.upatras.gr (Konstantinos Katsanos).
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Several randomised controlled trials (RCTs) have already
shown that paclitaxel coated balloons significantly reduce
the rates of vessel re-stenosis and target lesion revascu-
larisation of the femoropopliteal artery in patients with
symptomatic peripheral arterial disease (PAD).1 Recently,
concerns have been raised about the long term risk of death
using paclitaxel coated devices in the femoropopliteal ar-
tery.2,3 However, inconsistencies between randomised and
real world evidence,4,5 coupled with the absence of a
plausible biological mechanism have fuelled an ongoing
unresolved controversy on the role of paclitaxel in periph-
eral endovascular procedures. An interim mortality analysis
of the SWEDEPAD randomised trial did not confirm a
heightened mortality risk in cases of paclitaxel treatment.6
Another more recent meta-analysis has claimed a signifi-
cant detriment to amputation free survival using paclitaxel
coated balloons in the infrapopliteal arteries for critical limb
ischaemia (CLI) and has further intensified the debate
around safety and effectiveness of paclitaxel coated bal-
loons in the periphery.7 Non-target embolisation of cyto-
toxic paclitaxel particulate material with long lasting tissue
residence has been put forward as a possible mechanism
for potential adverse limb events.7 An updated systematic
review and meta-analysis of RCTs was performed to inves-
tigate the risk of major amputation associated using pacli-
taxel coated balloons in the lower limbs.MATERIALS AND METHODS
PICO tool and selection criteria
The design of the present systematic review and meta-
analysis complied with the PRISMA (Preferred Reporting
Items for Systematic reviews and Meta-Analyses) state-
ment.8 The focus was on major amputations only, because
other measures of safety and clinical effectiveness have
already been thoroughly reported.1 The PICO tool (Patient,
Intervention, Comparison, Outcome)9 was used to define
the scientific question as follows: “In patients suffering from
peripheral arterial disease, is treatment of the peripheral
(femoropopliteal and infrapopliteal) arteries with paclitaxel
coated balloons, compared with control treatment, safe and
effective in preventing major amputation in PAD?”. Each
study was assessed for potential inclusion in the current
meta-analysis on the basis of the following eligibility
criteria: (1) only RCTs were considered for inclusion, (2) all
types of paclitaxel coated balloon catheters were eligible
provided that they were applied in the lower limb arteries,
(3) selection allowed for both femoropopliteal and infra-
popliteal arteries of the lower limbs, (4) the target popu-
lation included patients presenting with symptoms ofcite this article as: Katsanos K et al., Risk of Major Amputation Following App
w and Meta-Analysis of Randomised Controlled Trials, European Journal of Vaperipheral arterial disease (intermittent claudication or CLI
documented by digital subtraction angiography, (4) follow
up of at least six months was available, and (5) the studies
reported counts of major amputations as part of their pri-
mary or secondary endpoints.
Search methods
This systematic review was registered in the PROSPERO
public database (http://www.crd.york.ac.uk/PROSPERO; ID
227761). The authors searched for RCTs that investigated
any type of paclitaxel coated or paclitaxel eluting balloon
catheter in the peripheral arteries for the treatment of
intermittent claudication or critical limb ischaemia. Elec-
tronic searches were conducted of PubMed (Medline),
EMBASE (Ovid), AMED, Scopus, CENTRAL, the PROSPERO,
and DARE databases. A broad bibliographic search was
performed using the search string “(drug-coated OR
paclitaxel-coated OR paclitaxel-eluting OR drug-eluting)
AND (randomized)”. Additional searches of the United
States Food and Drug Administration (FDA), European
Medicines Agency (EMA), United Kingdom Medicines and
Healthcare products Regulatory Agency (MHRA), Japanese
Pharmaceuticals and Medical Devices Agency (PMDA),
Japanese University Hospital Medical Information Network
Clinical Trials Registry (UMIN-CTR), Chinese Clinical Trials
Registry (ChiCTR), and United States National Library of
Medicine clinical trials database, and online archives of in-
ternational cardiovascular conferences were performed
including the terms “femoral”, “popliteal”, “femo-
ropopliteal”, “restenosis”, “target lesion revascularization”,
“peripheral”, “angioplasty”, “stent”, “tibial”, “infrapopliteal”,
“below knee”, “balloon”, “paclitaxel-coated”, “paclitaxel-
eluting”, “drug-coated”, “drug-eluting”, “peripheral arterial
disease”, “peripheral vascular disease”, “intermittent clau-
dication”, “critical limb ischaemia”, “plain balloon angio-
plasty”, “percutaneous transluminal angioplasty”, “clinical
trial”, “multi-center”, “randomized”, “controlled trial”, and
various pertinent terms with the corresponding Medical
Subjects Headings (MeSH) using Boolean syntax. The liter-
ature search was last updated on 20 February 2021. There
were no restrictions on publication language, publication
date, or publication status.
Data extraction and primary outcome
A standardised data extraction form was used to collect the
following information from all selected studies: (1) charac-
teristics of the study design methods (randomisation,
blinding, concealment of allocation, dropouts, outcome
reporting, risk of bias); (2) patient and limb sample size and
baseline clinical characteristics; (3) Rutherford classification
of peripheral vascular disease; (4) description of active druglication of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic
scular and Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2021.05.027
Records identified through
database searches




Total records screened (n = 4 395)
Articles chosen based on title and abstract (n = 857)
Records excluded based on
eligibility criteria (n = 806)
Studies with double zero
events excluded (n = 19)
Studies included in evidence synthesis (n = 21)































Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram of
literature search and selection of randomised controlled trials on paclitaxel coated balloons in peripheral
arterial disease.
Meta-analysis: Amputation Risk with Paclitaxel-Coated Balloons 3coated balloon (DCB) device and control endovascular
treatment; and (5) major amputation counts at different
follow up time intervals. The primary outcome measure was
set at major amputation defined as any reported limb loss
of the index limb above the ankle. Major amputations were
analysed on an intention to treat approach. Minor ampu-
tations were excluded from the present analysis.
Risk of bias and certainty of evidence
Risk of bias assessment employed the revised Cochrane
Collaboration’s tool for assessing risk of bias (RoB 2
tool).10,11 The latter tool evaluates potential risk of bias for
five domains: (1) randomisation process, (2) deviation from
intended interventions, (3) missing outcome data, (4)
measurement of outcomes, and (5) selection of the re-
ported results. Certainty of evidence was assessed with the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) system, which considers risk of
bias, imprecision, indirectness, inconsistency, and publica-
tion bias of the observed treatment effect as potential
reasons for downgrading the level of confidence.
Conversely, certainty about the quality of the evidence can
be upgraded for large effect size or presence of a dose
response gradient.12
Sensitivity and subgroup analyses
Heterogeneity was evaluated with the Cochran’s Q (chi
square) and the I2 statistical test, while small study effects and
publication bias were assessed by visual inspection of funnel
plots asymmetry and quantitatively with the Egger’s linear
regression test.13 Several sensitivity and subgroup analyses of
the primary endpoint were performed to assess consistency
and robustness of the summary treatment effect. Subgroups
of different paclitaxel coated balloons based on paclitaxel
concentration (2.0 mg/mm2 vs. 3.0 vs. 3.5 mg/mm2) were
analysed. Leave one out meta-analysis and combinatorialPlease cite this article as: Katsanos K et al., Risk of Major Amputation Following App
Review and Meta-Analysis of Randomised Controlled Trials, European Journal of Vameta-analysis were applied to test for influential studies
(single cases or clusters of studies), interrogate between
study heterogeneity, and better visualise the distribution of
the pooled effect estimate after examining all possible study
combinations (2k-1, where k is the number of selected RCTs).14
Attrition bias was assessed first by comparing dropouts rates
and consent withdrawals between treatment arms, and
second by multiple imputation of right censored cases
assuming departure from independent censoring.15,16
Dose response meta-analysis
In the search for epidemiological evidence of causation, a
quantitative multivariable dose response meta-analysis was
undertaken to investigate the potential presence of a bio-
logical gradient using the methods of Crippa et al.17 Cu-
mulative intraprocedural paclitaxel dose was extracted from
published material or inferred from the product of the
paclitaxel coated balloon concentration [C] and treated
vessel surface area (surface area of a cylinder based on
reported lesion length [L] and vessel diameter [D]). It is
widely recommended (and explicitly stated in most RCT
protocols) that DCB application is performed with a longer
balloon compared with the target lesion length to avoid
geographic miss. Hence, lesion length L was corrected for
routine practice of longer DCB sizing based on a validation
model of six RCTs that reported actual paclitaxel dose
delivered (Supplementary material). Linear and non-linear
dose response models were explored.
Statistical methods
Studies with zero events in both study arms were excluded
from numerical synthesis according to Cochrane guidance
(Cochrane handbook chapter 16.9.3). Quantitative synthesis
of the included RCTs was performed with the “meta”,
“dmetar”, “metafor”, “survival”, “coxme”, “Informative-
Censoring”, and “dosresmeta” packages in R languagelication of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic
scular and Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2021.05.027
Table 1. Design characteristics of included randomised controlled trials on paclitaxel coated balloons in peripheral arterial disease
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* All included randomised controlled trials tested paclitaxel coated balloons for treatment of peripheral arterial disease. In the DRECOREST-I
trial, paclitaxel drug coated balloons (DCB) were randomised vs. plain balloon angioplasty for failing bypass surgery. In the COPA-CABANA
randomised study, DCB were investigated for treatment of in stent restenosis and the non-randomised double dose cohort for recurrent in
stent restenosis was excluded. The DEBELLUM study randomised both femoropopliteal and infrapopliteal lesions. In the PACUS trial, DCB
were randomised vs. a combination of high frequency low intensity intravascular ultrasound therapy and contrast dissolved liquid paclitaxel
(1.0 mg / mm3) delivered in the femoropopliteal treatment area under distal balloon occlusion and aspirated with a 50 mL syringe after 60
sec. Total dose of liquid paclitaxel in the control arm was accounted for in the multivariable dose response meta-analysis. In the RAPID


















HR = 1.66 (95% CI 1.14–2.42)
p = .008
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Figure 2. Cumulative hazard functions (time to event) of major
amputations in the two treatment arms of paclitaxel coated
balloon and of control balloon in patients with peripheral arterial
disease. A one stage proportional hazards Cox model stratified at
trial level (random effect) was applied.
Meta-analysis: Amputation Risk with Paclitaxel-Coated Balloons 5environment (version 3.6.3). Categorical variables were
expressed as counts and percentages, and continuous var-
iables as means  standard deviation. To address differ-
ences in follow up period and number of participants who
either died or were lost to follow up (LTFU), the primary
endpoint was summarised on the log hazard scale as rec-
ommended for time to event outcomes.18 Study specific
hazard ratios (HR) and respective variances were sourced
from individual publications or calculated from published
KaplaneMeier curves and survival tables by applying the
methods of Tierney et al.19 and Guyot et al.20 for extraction
of individual time to event patient outcomes. The latter
have shown high reproducibility and excellent accuracy for
calculation of survival probabilities and HRs. For missing or
incomplete data, the principal investigators were contacted,
and individual patient time to event data were requested.
Examples of time to event analyses are given in the Sup-
plementary material (Fig. S1).
Summary statistics were expressed as HRs and the
associated 95% confidence intervals (CI). One and two stage
models were employed for the current meta-analysis.21
Number needed to harm (NNH) was calculated in case of
significant findings at the end of the reported follow up
period. Hazard functions of major amputations were pooled
with a fixed effects model in the absence of significant
statistical heterogeneity. A stratified Cox model with a
random effect for each trial was applied in case of the one
stage patient level model,22 whereas an inverse variance
weighting method was used for the two stage trial level
model.18 To address the risk of informative censoring,
bootstrap multiple imputation methods were used to
impute censored failure times from the predictive distri-
bution of the observed failure times.15 A total of n ¼ 100
datasets were imputed and Rubin’s rules were applied to
pool parameter estimates after fitting a one stage stratified
Cox model in each of the imputed datasets. For the dose
response meta-analysis, a one stage random effects model
was applied with restricted maximum likelihood using trialPlease cite this article as: Katsanos K et al., Risk of Major Amputation Following App
Review and Meta-Analysis of Randomised Controlled Trials, European Journal of Valevel summary effects on the log hazard scale.17 In case of
the dose response model, a restricted cubic spline model
with three knots located at the 10th, 50th, and 90th per-
centiles was fitted because splines are more advantageous
over conventional non-linear models.23 The level of statis-
tical significance was set at a ¼ .05.RESULTS
The literature search yielded 4 395 articles eligible for
further analysis. Of those, 857 publications were considered
for inclusion based on their title and abstract. Finally, 51
items reporting the results of 40 RCTs in total were included
for further in depth full text analysis after excluding studies
that did not meet the predefined inclusion criteria (PRISMA
selection process in Fig. 1). Design characteristics of testedlication of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic
scular and Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2021.05.027
6 Konstantinos Katsanos et al.devices are outlined in Table S1. Nineteen RCTs reported
zero events of major amputations in both study arms and
were excluded from further numerical analysis (Table S2). In
all, 21 RCTs with 3 760 lower limbs were eventually included
in the quantitative evidence synthesis. The primary char-
acteristics of the 21 selected RCTs are outlined in Table 1.
Out of the 21 RCTs, four studies with 1 375 cases tested a
2.0 mg/mm2 paclitaxel coated balloon,24e27 10 studies with
1 260 patients tested a variety of 3.0 mg/mm2 paclitaxel
coated balloon catheters,18,28e39 and seven studies with 1
125 patients investigated the highest 3.5 mg/mm2 paclitaxel
coating technology.40e46 Paclitaxel coated balloons were
used in the femoropopliteal arteries in 13 studies with 2
323 lower limbs, in the infrapopliteal arteries in seven
studies with 1 366 limbs, whereas one study with 71 limbs
enrolled both the femoropopliteal and infrapopliteal seg-
ments.43 There was a largely balanced distribution of
baseline patient and lesion characteristics across all studies
as described in detail in previously published meta-analyses.
Overall, mean patient age ranged between 67 and 76 years,
randomised subjects were predominantly males, and the
most prevalent risk factors included smoking, diabetes,






























Figure 3. Forest plot of the two stage meta-analysis of tr
paclitaxel coated balloon versus control balloon angiopla
were pooled with inverse variance weighting. There was n
effects models are shown. CI ¼ confidence interval.
Please cite this article as: Katsanos K et al., Risk of Major Amputation Following App
Review and Meta-Analysis of Randomised Controlled Trials, European Journal of VaThe enrolled patient population encompassed 1 972 lower
limbs (52%) suffering from short distance intermittent clau-
dication and 1 788 limbs presenting with CLI (48%). A wide
range of lesions was treated with a weighted average lesion
length of 10 cm (Table 1). The median RCT follow up period
was two years (range 0.5e5 years). Of 21 RCTs, 16 studies
were designed as randomised multicentre trials and five as
single centre trials.33,40,43e45 Overall risk of bias was mostly
low to moderate for all included trials. Randomisation and
allocation concealment were performed adequately in most
cases and there was low risk of outcome data missingness or
selective data reporting. There were some concerns about
performance bias in all studies because none of them was
executed in a double blind fashion. This was reflected
accordingly in the second domain of the RoB-2 tool (Fig. S2;
revised Cochrane Risk of Bias tool).
Major amputations
In all, 21 RCTs reported 128 events in 3 760 lower limbs
after a median individual patient follow up period of two
years (max. five years). There were 87 major amputations of
2 216 limbs in the paclitaxel arms (4.0% crude risk)
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Figure 4. Cumulative hazard functions of major amputations in
the two treatment arms of paclitaxel coated balloon and of control
balloon for (A) femoropopliteal and (B) infrapopliteal arteries in
patients with peripheral arterial disease. A one stage proportional
hazards Cox model stratified at trial level (random effect) was
applied.
Meta-analysis: Amputation Risk with Paclitaxel-Coated Balloons 7control arms (2.7% crude risk). Application of paclitaxel
coated balloons was associated with a significantly higher
risk of major amputation with a pooled HR of 1.66 (95% CI
1.14 e 2.42; p ¼ .008, one stage stratified Cox model).
Cumulative hazard functions in the two treatment arms are
shown in Fig. 2. The prediction interval for the two stage
model was 95% CI 1.10 e 2.46 (Fig. 3). There was no sig-
nificant statistical heterogeneity between studies (I2 ¼ 0%,
p ¼ .77). In subgroup analyses, the observed amputation
risk was consistent for both femoropopliteal (p ¼ .055) and
infrapopliteal (p ¼ .055) vessels (Fig. 4). Eleven of the 21
RCTs enrolled predominantly CLI patients. The crude
amputation risk in CLI trials was 7.2% (74 events of 1 022
limbs) in case of paclitaxel coated treatment vs. 4.7% (36
events of 766 limbs) in controls. The risk of major ampu-
tation was significant in trials including mostly CLI patients
(HR 1.56, 95% CI 1.04 e 2.33; p ¼ .03), but not in trials
enlisting intermittent claudication patients (HR 2.47, 95% CI
0.87 e 6.97; p ¼ .088) (Fig. 5). The corresponding NNH for
CLI was 35.
In the dose response meta-analysis, a significant dose
dependent association between peri-procedural paclitaxel
coated balloon exposure and risk of major amputation was
detected (Fig. 6). In the log linear model, there was a
significantly higher relative risk of major amputation by 1.12
times per every paclitaxel milligram delivered (95% CI 1.04
e 1.21, p ¼ .003) without any significant heterogeneity
across studies (I2 ¼ 0%, p ¼ .87). Because of evidence of
departure from linearity (Wald test p ¼ .007 of regression
coefficients) and improved goodness of fit, a non-linear
restricted cubic spline model is presented instead (Fig. 6).
Amputation risk was accelerated over increasing paclitaxel
dose. Predicted amputation risk was 1.7 times higher (95%
CI 1.09 e 2.53) at the 5 mg paclitaxel exposure level and 4.4
times higher (95% CI 1.59 e 12.1) at the 10 mg exposure
level (chi-square model p ¼ .007). Findings of the acceler-
ated dose response gradient were very similar with and
without the treated lesion length correction factor (Dose
response section, Supplementary material).
In the sensitivity tests, the pooled HR was congruent
across leave one out meta-analysis without any influential
studies (Table S3). Combinatorial meta-analysis showed a
homogeneous set of studies without any outliers or influ-
ential clusters, and absence of between study statistical
heterogeneity. The pooled estimate demonstrated a sym-
metric, unimodal distribution indicative of treatment effect
homogeneity (Fig. 7). Different statistical models produced
similar results with little variation in the magnitude and
precision of the observed effect size (Table S4). For multi-
centre trials only, the calculated HR was 1.71 (95% CI 1.13 e
2.59; p ¼ .011). Reported rates of dropout and consent
withdrawal were low and similar between the paclitaxel and
control groups (7.6 vs. 7.3%, p ¼ .71; Table S5). Pooled
multiple imputed HR was 1.69 (95% CI 1.18 e 2.41, p ¼
.004).
Subanalyses of different paclitaxel dose densities were
numerically consistent but exhibited wide confidence in-
tervals and only the higher 3.5 mg/mm2 dose platformPlease cite this article as: Katsanos K et al., Risk of Major Amputation Following App
Review and Meta-Analysis of Randomised Controlled Trials, European Journal of Vareached the level of statistical significance with an HR of
1.92 (95% CI 1.06 e 3.48; p ¼ .033, Fig. S3). Leaving one
excipient out meta-analysis confirmed also that the
observed effect was dominated by the higher 3.5 mg/mm2
e Urea design (Table S4). There was no visual asymmetry of
the funnel plot to suggest publication bias (Egger’s test ¼
0.09; p ¼ .80; Figs S4 and S5). Level of certainty in evidence
was downrated from high to moderate because of sparse
events in some studies implying imprecision. Complete
numerical results are provided in detail in the Supplemen-
tary material (Table S6).DISCUSSION
Concerns have been raised about the long term risk of all
cause death using paclitaxel coated devices in the pe-
ripheral arteries. Study level meta-analyses have demon-
strated a statistically significant higher long term risk oflication of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic
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Figure 5. Cumulative hazard functions of major amputations in
the two treatment arms of paclitaxel coated balloon and of control
balloon for (A) intermittent claudication (IC) and (B) critical limb
ischaemia (CLI) in patients with peripheral arterial disease. Se-
lection of studies was based on dichotomy of trial level CLI rates
(median proportion 42%). A one stage proportional hazards Cox
model stratified at trial level (random effect) was applied.





















Figure 6. Dose response relationship between the amputation log
hazard (logHR) point estimate and the cumulative paclitaxel
coated balloon dose in milligrams delivered at index procedure of
balloon angioplasty for peripheral arterial disease. The blue line
denotes the log linear model and red line (with shaded 95%
confidence bands) shows the non-linear spline model (three knots
at the 10th, 50th, and 90th percentiles; Chi square model p ¼


























Figure 7. Combinatorial meta-analysis of study statistical het-
erogeneity. A random sample of 106 model fits was calculated of a
total of 220 study combinations. Scatterplot of heterogeneity I2
against the log hazard (logHR) point estimate shows a homoge-
neous distribution of the summary effect without any influential
subset of studies. Histograms with smoothed kernel densities of
both effect size and I2 estimates have been drawn and are juxta-
posed on the respective axes.
8 Konstantinos Katsanos et al.death associated with the application of paclitaxel coated
devices in the femoropopliteal artery.2,47 The United States
Federal Drug Agency (FDA) conducted internal meta-
analyses of industry sponsored RCTs and corroborated
the presence of an inexplicable late mortality signal.48
Ultimately, an individual patient data meta-analysis of
eight FDA approved paclitaxel coated devices (paclitaxel
balloons and stents) observed a significant 4.6% absolute
increased long term mortality risk associated with pacli-
taxel coated device use compared with balloon angio-
plasty.3 In parallel, results of a multitude of observational
real world studies, mostly in the form of retrospective
analyses of administrative patient records and reimburse-
ment claims in the United States and in Germany, have
produced conflicting results claiming adequate safety andPlease cite this article as: Katsanos K et al., Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic
Review and Meta-Analysis of Randomised Controlled Trials, European Journal of Vascular and Endovascular Surgery, https://doi.org/10.1016/j.ejvs.2021.05.027
Meta-analysis: Amputation Risk with Paclitaxel-Coated Balloons 9occasionally some survival benefit associated with pacli-
taxel use in peripheral vascular disease.4,5,49,50 A recent
interim report from the SWEDEPAD registry RCT did not
show an overall mortality difference, but 2.0 mg/mm2
paclitaxel coated balloons were used in 41% of the cases.
Long term HR was 1.18 (95% CI 0.72 e 1.93) for inter-
mittent claudication, which is similar to the non-significant
point estimate reported by Katsanos et al. for the low
dose devices (RR 1.27, 95% CI 0.70 e 2.32).2
To the present authors’ knowledge, this analysis is the first
to document a statistically significant higher long term risk of
major amputation associated with the application of pacli-
taxel coated balloons in the peripheral arteries.The summary
effect demonstrated a 66% higher relative risk of major
amputation in the paclitaxel coated treated limbs. In partic-
ular, the finding affected mostly the CLI population with a
NNH of 35. In addition, there was good evidence of a signif-
icant non-linear dose response relationship with accelerated
risk per cumulative paclitaxel dose. The results showed a
consistent and homogeneous signal of potential harm for
both femoropopliteal and infrapopliteal vessels. These find-
ings are particularly worrisome considering that there is
already widespread use of several paclitaxel coated balloon
catheters, especially in higher risk peripheral vascular pa-
tients per the latest FDA guidance letter.51 A previous meta-
analysis also raised concerns about poorer amputation free
survival (composite endpoint of death and major amputa-
tion) using paclitaxel coated balloons in the infrapopliteal
arteries.7 Interestingly, real world outcomes in the German
population (Barmer Health Insurance claims) reported
numerically higher five year rates of limb loss in the femo-
ropopliteal segment for intermittent claudication (1.0 vs.
0.8%) and in the infrapopliteal segment for CLI treatment (7.6
vs. 6.5%) for paclitaxel devices (propensity matched com-
parisons) contrary to the claimed survival benefit.49,50
Certainly, all paclitaxel coated balloon catheters suffer
from distal embolisation of significant amounts of paclitaxel
particulatematerial when inflated in the circulatory system.52
It has been long shown that less than 10% of the paclitaxel
load is being transferred to the treated vessel wall in case of
drug coated balloon catheters and as much as 90% escapes
into the distal circulation.53,54 Hence, downstream showers
of cytotoxic solid state paclitaxel material combined with its
long lasting tissue residence remains the most likely hy-
pothesis for the herein noted increased risk of amputation.
Tissue absorption of solid state paclitaxel is far lower than the
rate of tissue metabolic clearance, resulting in local presence
of the drug for several months. Consequently, long term tis-
sue bioavailability of paclitaxel depends more on its low
solubility (i.e., anhydrous and dihydrate less soluble than
amorphous) and the total amount of paclitaxel delivered
during the index procedure.55 Furthermore, time scale nu-
merical analyses support the notion that paclitaxel tissue
retention is governed by an intricate interplay of paclitaxel
crystallinity, coating/excipient dissolution kinetics, saturation
levels of local tissue binding sites, and diffusion barriers
potentially imposed by atherosclerosis.56 For example,
calcified plaque material may impede diffusion of paclitaxelPlease cite this article as: Katsanos K et al., Risk of Major Amputation Following App
Review and Meta-Analysis of Randomised Controlled Trials, European Journal of Vaup to 100 fold compared with preclinical observations in
healthy animal experiments.55
Overall, paclitaxel pharmacokinetics appear to be multi-
phasic and non-linear leading to long lasting tissue resi-
dence with unknown long term biological effects. In the
literature, there are scarce reports of vascular fibrinoid
necrosis, aneurysmal degeneration, small vessel inflamma-
tion, and focal downstream skeletal muscle necrosis as the
most likely result of local paclitaxel toxicity.57,58 Hence, the
present authors believe that systemic release and down-
stream embolisation of cytotoxic paclitaxel particles in
combination with the underlying ischaemia and inflamma-
tion in the case of CLI is the most likely explanation for the
noted risk of amputation. Of note, the present findings
relate only to paclitaxel coated balloon catheters. On the
contrary, in the PADI trial, use of coronary polymer coated
paclitaxel eluting stents in the infrapopliteal arteries have
been shown to be effective in reducing major amputations
at five years and safe at 10 years of follow up.59 Consider-
ations of major differences in the total paclitaxel dose
(more than an order of magnitude less in case of coronary
paclitaxel eluting stents compared with DCBs) and release
kinetics (polymer controlled sustained release vs. acute
balloon burst) lend weight to the primary hypothesis of
downstream paclitaxel particulate showers as the main
reason of the observed higher risk of major amputations
using paclitaxel coated balloons in the peripheral arteries.
Intersociety guidelines published in 2017 on the manage-
ment of peripheral vascular disease have recommended
paclitaxel coated balloons and stents for short femoropopliteal
lesions (< 25 cm; recommendation class IIb);60 however, the
updated 2019 Global Vascular Guidelines (GVG) noted the
identified mortality risk for intermittent claudication and the
ongoing investigations of regulatory bodies and independent
research teams to further clarify those concerns
(Addendum).61 Considering the present findings, the authors
agree with the recommendation of the GVG steering com-
mittee that appropriately powered and controlled clinical
studies need to continue investigating the risks and benefits of
different paclitaxel coated devices for critical limb ischaemia
treatments. However, caution and consideration of the po-
tential mortality and herein presented amputation risks must
be exercised outside the setting of clinical trials.2,7
The present work has several limitations. First, some RCTs
did not report any major amputations in either arm (mostly
claudicants with one year follow up), whereas some of the 21
analysed RCTs reported sparse events, and this may have
given rise to imprecision. Therefore, certainty of evidence
was downrated from high to moderate regardless of the
positive dose response association. Patient level time to
event data were extracted and analysed with a one stage
model to increase power and precision and there was also
consistent size and direction of the summary effect in the
various subgroup and sensitivity tests (leave one out, mul-
ticentre, and different fitted models), but still, the reported
amputation risk may be driven by sampling errors or even
pure chance considering the overall low event rates. In
addition, the low dose balloons appeared to be safe, but thislication of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic
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10 Konstantinos Katsanos et al.may be because of the small number of events and lack of
adequate statistical power to detect a true effect. Second,
good evidence was found of a biological gradient and the risk
of amputation was potentiated in the 3.5 mg/mm2 subset of
studies using the IN.PACT technology with urea excipient that
remains widely used in the femoropopliteal segment.
Certainly, considering differences in paclitaxel crystallinity
and excipient formulation across different balloon platforms,
the presented dose response meta-analysis is probably
rudimentary and could not account for variations of tissue
bioavailability across different devices. Future trials should
include larger sample sizes and be adequately powered to
detect potential differences of major amputations between
uncoated and coated balloons, or even between different
paclitaxel coated balloon designs (dosages and/or excipi-
ents). Third, other sources of clinical heterogeneity and po-
tential variable interactions could not be explored in the
absence of individual patient covariates. It is likely that
different dose and excipient combinations may produce
different clinical results. Fourth, amputation rates consti-
tuted a secondary safety endpoint in all studies and the
actual clinical indications to perform a major amputation
were not reported in the studies to help distinguish between
infectious, ischaemic, or neuropathic causes of major limb
loss. Finally, included RCTs were published over a period of
more than a decade, none of them was powered for limb
salvage outcomes, and improvements in general medical
management or in the design of newer paclitaxel coated
balloon platforms over time could not be accounted for.
In conclusion, there appears to be heightened risk of
major amputation after paclitaxel coated balloon applica-
tion in the femoropopliteal and infrapopliteal arteries,
especially in the setting of critical limb ischaemia. Down-
stream embolisation of cytotoxic paclitaxel particulate ma-
terial would be the most likely explanation. Considering the
widespread use of those devices in high risk vascular pa-
tients, this observation needs to be urgently refuted within
the context of properly designed randomised studies.
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